| Literature DB >> 26147942 |
Marco Coral-Almeida1, Sarah Gabriël2, Emmanuel Nji Abatih2, Nicolas Praet2, Washington Benitez3, Pierre Dorny4.
Abstract
BACKGROUND: Taenia solium cysticercosis is a zoonotic neglected disease responsible for severe health disorders such as seizures and death. Understanding the epidemiology of human cysticercosis (HCC) in endemic regions will help to expose critical information about the transmission of the disease, which could be used to design efficient control programs. This review gathered serological data on apparent prevalence of T. solium circulating antigens and/or seroprevalence of T. solium antibodies, apparent prevalence of human taeniasis and risk factors for HCC from endemic communities in order to understand the differences in exposure to the parasite and active infections with T. solium metacestodes in endemic areas around the world.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26147942 PMCID: PMC4493064 DOI: 10.1371/journal.pntd.0003919
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Flow diagram describing literature search and selection of studies (PRISMA 2009 flow chart).
Sero-epidemiological studies using Ag-ELISA and/or EITB for human cysticercosis in Africa.
| Author | YOP | Country | Location | Circulating Ag positive cases/total participants | Circulating Ag prevalence (%) [95%CI] | Ab positive cases/total participants | Ab seroprevalence (%) [95%CI] |
|---|---|---|---|---|---|---|---|
| Nguekam et al. | 2003 | Cameroon | West province | 34 | 0.68 [0.47–0.95] | ||
| Carabin et al. | 2009 | Burkina Faso | Sanguié, Kadogo, Oubritenga | 48 | 6.29 [4.67–8.25] | ||
| Kanobana et al. | 2011 | Dem. Rep. of Congo | Bas-Congo | 204 | 21.63 [19–24.4] | ||
| Secka et al. | 2011 | Senegal | Ziguinchor | 31 | 7.69 [5.28–10.74] | 31/403 | 7.69 [5.28–10.74] |
| Nitiéma et al. | 2012 | Burkina Faso | Sanguié, Kadogo, Oubritenga | 45 | 6.13 [4.50–8.12] | ||
| Mwape et al. | 2012 | Zambia | Estern Province | 41 | 5.80 [4.19–7.8] | ||
| Mwape et al. | 2013 | Zambia | Eastern Province | 141 | 12.49 [10.61–14.56] | 57/165 | 34.55 [27.32–47.33] |
| Mwanjali et al. | 2013 | Tanzania | Mbeya | 139 | 16.75 [14.27–19.46] | ||
| Thomas | 2014 | Kenya | Western and Nyanza | 169 | 8.07 [6.94–9.32] | ||
|
|
|
|
|
| |||
|
|
|
|
Legend: YOP: Year of publication; Location: Corresponds to the Province, State, Region or Department in which the communities where the studies took place are located; Ag: Antigen detection based on Ag-ELISA results; Ab: Antibody detection based on EITB results; 95% CI: 95% Confidence Intervals; REMEP: Random Effects Model Estimated Prevalence; Dem. Rep. of Congo: Democratic Republic of Congo.
a: Results obtained from B158/B60 Ag-ELISA
b: Results obtained from HP10 Ag-ELISA.
Sero-epidemiological studies using Ag-ELISA and/or EITB for human cysticercosis in Latin America.
| Author | YOP | Country | Location | Circulating Ag positive cases/Total participants | Circulating Ag Prevalence (%) [95%CI] | Ab positive cases/Total participants | Ab seroprevalence (%) [95%CI] |
|---|---|---|---|---|---|---|---|
| Díaz et al. | 1992 | Peru | San Martin | 30/371 | 8.09 [5.52–11.34] | ||
| Sarti et al. | 1992 | Mexico | Morelos | 167/1546 | 10.80 [9.3–12.46] | ||
| Sarti et al. | 1994 | Mexico | Michoacan | 49/1005 | 4.88 [3.63–6.39] | ||
| García-Noval et al. | 1996 | Guatemala | Jutiapa | 207/1542 | 13.42 [11.76–15.23] | ||
| Sanchez et al. | 1998 | Honduras | Francisco Morazán | 63/404 | 15.59 [12.2–19.5] | ||
| García et al. | 1998 | Peru | Cusco | 24/102 | 23.8 [15.69–32.96] | ||
| Sanchez et al. | 1999 | Honduras | Olancho | 80/480 | 16.67 [13.44–20.31] | ||
| García et al. | 1999 | Peru | Cusco | 14/108 | 12.96 [7.27–20.8] | ||
| Sarti et al. | 2000 | Mexico | Morelos | 91/1603 | 5.68 [4.59–6.92] | ||
| García et al. | 2001 | Peru | Piura | 76/482 | 15.77 [12.63–19.33] | ||
| Peru | Junín | 140/398 | 35.18 [30.48–40.1] | ||||
| Colombia | N.A. | 23/750 | 3.07 [1.95–4.57] | ||||
| Gomes et al. | 2002 | Brazil | Bahia | 11/694 | 1.59 [0.79–2.82] | ||
| García et al. | 2003 | Peru | Junín | 355/2583 | 13.74 [12.44–15.13] | ||
| Ferrer et al. | 2003 | Venezuela | Carabobo | 27 | 9.12 [6.10–12.99] | ||
| Venezuela | Lara | 37 | 6.08 [4.32–8.29] | ||||
| Venezuela | Lara | 20 | 6.56 [4.05–9.95] | ||||
| Agudelo-Flores & Palacio | 2003 | Colombia | Antioquia | 12/661 | 1.82 [0.94–3.15] | ||
| Moro et al. | 2003 | Peru | Lima | 66/316 | 20.89 [16.54–25.79] | ||
| Rodriguez et al. | 2003 | Ecuador | Pichincha & Imbabura | 215 | 4.99 [4.36–5.69] | ||
| Montano et al. | 2005 | Peru | Tumbes | 200/825 | 24.24 [21.35–27.32] | ||
| Rodriguez et al. | 2006 | Ecuador | Loja | 18 | 2.25 [1.34–3.53] | 40/100 | 40.00 [30.33–50.23] |
| Agudelo-Flores et al. | 2009 | Colombia | Chocó | 4/46 | 8.70 [2.42–20.79] | ||
| Lescano et al. | 2009 | Peru | Tumbes | 196/803 | 24.41 [21.47–27.53] | ||
| Praet et al. | 2010 | Ecuador | Loja | 23 | 2.90 [1.84–4.31] | 202/807 | 25.03 [22.08–28.17] |
| Coral et al. | 2014 | Ecuador | Loja | 7 | 0.94 [0.38–1.93] | 232/743 | 31.22 [27.9–34.69] |
|
|
|
|
|
| |||
|
|
|
|
Legend: YOP: Year of publication; Location: Corresponds to the Province, State, Region or Department in which the communities are located where the studies took place; Ag: Antigen detection based on Ag-ELISA results; Ab: Antibody detection based on EITB results; 95% CI: 95% Confidence Intervals; REMEP: Random Effects Model Estimated Prevalence
a: Results obtained from B158/B60 Ag-ELISA
b: Results obtained from HP10 Ag-ELISA
N.A.: Not available.
Sero-epidemiological studies using Ag-ELISA and/or EITB for human cysticercosis in Asia.
| Author | YOP | Country | Location | Circulating Ag positive cases/total participants | Circulating Ag prevalence (%) [95%CI] | Ab positive cases/total participants | Ab seroprevalence (%) [95%CI] |
|---|---|---|---|---|---|---|---|
| Theis et al. | 1994 | Indonesia | Bali | 94/746 | 12.60 [10.3–15.2] | ||
| Erhart et al. | 2002 | Viet Nam | Bac Ninh | 12 | 5.71 [2.99–9.77] | ||
| Somers et al. | 2006 | Viet Nam | Bac Kan | 16 | 5.28 [3.05–8.43] | ||
| Viet Nam | Ha Tinh | 1 | 0.57 [0.01–3.14] | ||||
| Raghava et al. | 2010 | India | Tamil Nadu | 46 | 4.79 [3.53–6.34] | 184/960 | 19.17 [16.72–21.8] |
| Jayaraman et al. | 2011 | India | Tamil Nadu | 48 | 4.51 [3.34–5.94] | ||
| Conlan et al. | 2012 | Laos | Oudomxay, Luangprabang, Huaphan, and Xiengkhuang | 29 | 2.22 [1.49–3.17] | ||
|
|
|
|
|
| |||
|
|
|
|
Legend: YOP: Year of publication; Location: Corresponds to the Province, State, Region or Department in which the communities are located where the studies took place; Ag: Antigen detection based on Ag-ELISA results; Ab: Antibody detection based on EITB results; 95% CI: 95% Confidence Intervals; REMEP: Random Effects Model Estimated Prevalence
a: Results obtained from B158/B60 Ag-ELISA
Fig 2Global distribution of the endemic countries where Ag-ELISA and/or EITB based epidemiological studies were held.
Light yellow represents the countries confirmed as endemic by the World Health Organization (WHO) until 2012 [66]. Circles represent the countries where Ag-ELISA based studies took place. Each color represents the average prevalence per country found from the selected articles in this review classified in 0 to 5 percent; 5 to 10 percent and more than 10 percent. Triangles represent the countries where EITB based studies took place. Each color represents the average prevalence per country found from the selected articles in this review classified in 0 to 5 percent; 5 to 10 percent and more than 10 percent.
Taeniasis reports from Africa, Latin America and Asia.
| Continent | Author | Year of publication | Country | Diagnostic Technique | Positive cases/ Total participants | Prevalence (%) [95%CI] |
|---|---|---|---|---|---|---|
| Africa | Kanobana et al. | 2011 | Dem. Rep. of Congo | Coprology | 3/816 | 0.37 [0.08–1.07] |
| Secka et al. | 2011 | Senegal | Direct fecal examination | 2/43 | 4.65 [0.57–15.81] | |
| FECT | 4/43 | 9.30 [2.59–22.14] | ||||
| worm expulsion and morphological identification | 1/43 | 2.33 [0.06–12.29] | ||||
| Mwape et al. | 2012 | Zambia | FECT | 2/718 | 0.28 [0.03–1.00] | |
| Copro-Ag ELISA | 45/712 | 6.32 [4.65–8.37] | ||||
| Mwanjali et al. | 2013 | Tanzania | Copro-Ag ELISA | 43/820 | 5.24 [3.82–7.00] | |
| EITB (rES38) | 34/820 | 4.15 [2.89–5.75] | ||||
| FECT | 9/820 | 1.10 [0.50–2.07] | ||||
| Mwape et al. | 2013 | Zambia | FECT | 0/226 | 0.00 [0.00–1.62 | |
| Copro-Ag ELISA | 27/226 | 11.95 [8.02–16.90] | ||||
| Thomas | 2014 | Kenya | Copro-Ag ELISA | 278/2003 | 13.88 [12.39–15.47] | |
| FECT | 4/2059 | 0.19 [0.05–0.50] | ||||
| Latin America | Diaz et al. | 1992 | Peru | microscopy, both directly and after FECT | 1/305 | 0.33 [0.01–1.81] |
| Sarti et al. | 1992 | Mexico | FECT | 4/1531 | 0.26 [0.07–0.67] | |
| Sarti et al. | 1994 | Mexico | FECT | 2/828 | 0.24 [0.03–0.87] | |
| García-Noval et al. | 1996 | Guatemala | FECT & Copro-Ag ELISA | 27/995 | 2.71 [1.80–3.92] | |
| Guatemala | FECT& Copro-Ag ELISA | 123/713 | 17.25 [14.55–20.23] | |||
| Sanchez et al. | 1998 | Honduras | FECT | 2/404 | 0.50 [0.06–1.78] | |
| Sanchez et al. | 1999 | Honduras | FECT | 12/480 | 2.50 [1.30–4.33] | |
| Sarti et al. | 2000 | Mexico | Copro-Ag ELISA | 16/1865 | 0.86 [0.49–1.39] | |
| FECT | 11/1865 | 0.59 [0.29–1.05] | ||||
| Gomes et al. | 2002 | Brazil | Copro-Ag ELISA | 26/577 | 4.51 [2.96–6.53] | |
| Rodriguez et al. | 2003 | Ecuador | FECT | 30/1935 | 1.55 [1.05–2.21] | |
| PCR-RFLP (identification) | 8/29 | 27.59 [12.73–47.24] | ||||
| García et al. | 2003 | Peru | microscopy, both directly and after FECT | 8/1317 | 0.61 [0.26–1.19] | |
| Copro-Ag ELISA | 45/1619 | 2.78 [2.03–3.70] | ||||
| Lescano et al. | 2009 | Peru | FECT | 11/898 | 1.22 [0.61–2.18] | |
| Praet et al. | 2010 | Ecuador | FECT | 0/674 | 0.00 [0.00–0.55 | |
| MSFT | 0/674 | 0.00 [0.00–0.55 | ||||
| Rodriguez et al. | 2006 | Ecuador | FECT | 14/958 | 1.46 [0.80–2.44] | |
| PCR-RFLP (identification) | 12/12 | 100 [73.54–100 | ||||
| Asia | Erhart et al. | 2002 | Viet Nam | FECT | 0/210 | 0.00 [0.00–1.74 |
| Somers et al. | 2006 | Viet Nam | Copro-Ag ELISA | 1/297 | 0.34 [0.01–1.86] | |
| KATO | 1/297 | 0.34 [0.01–1.86] | ||||
| Worm expulsion & PCR-RFLP for identification | 1/297 | 0.34 [0.01–1.86] | ||||
| Viet Nam | Copro-Ag ELISA | 3/166 | 1.81 [0.37–5.19] | |||
| KATO | 2/166 | 1.20 [0.15–4.28] | ||||
| Worm expulsion and PCR-RFLP for identification | 1/166 | 0.60 [0.01–3.31] | ||||
| Raghava et al. | 2010 | India | Copro-Ag ELISA | 22/729 | 3.02 [1.90–4.53] | |
| Jayaraman et al. | 2011 | India | Copro-Ag ELISA | 6/729 | 0.82 [0.30–1.78] | |
| Conlan et al. | 2012 | Laos | FECT and self-report | 110/1306 | 8.42 [6.97–10.06] |
Legend: FECT: Formalin-ether concentration technique; KATO: Kato-Katz technique; MSFT: Magnesium sulphate flotation technique; PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism; ELISA: Enzyme-Linked Immunosorbent Assay; Copro-Ag ELISA: Coproantigen ELISA; EITB: Enzyme-linked Immunoelectrotransfer Blot; Dem. Rep. of Congo: Democratic Republic of Congo.
a: Fecal samples were provided voluntarily from participants when not specified otherwise
*: One sided 97.5% confidence interval
**: Technique applied in fecal samples from seropositive subjects for T. solium antibodies or circulating antigens
Coprology†: Technique not defined
Factors affecting serological variations of human cysticercosis infection and exposure to T. solium eggs.
| Human host (Accidental intermediate host) | Parasite ( | Environment | |
|---|---|---|---|
| Factors affecting exposure in a population | Age (time exposed to the parasite)[ | Number of adult parasites present (tapeworm carriers, hotspots) [ | |
| (Presence of detectable antibodies) | Gender (Role played in different cultures) | Number of eggs dispersed in the environment [ | |
| Occupation | Egg survival (egg viability) on climatic conditions: Temperature, Humidity, seasonality[ | ||
| Hygiene, sanitation, behavioral practices, agricultural & cooking practices[ | |||
| Area (endemic) | |||
| Factors affecting active infections in a population | Age (Immunosenescence) [ |
| Egg survival (egg viability) on climatic conditions: Temperature, Humidity, seasonality[ |
| (Presence of circulating antigens) | Gender (Hormonal profile)[ | Presence of other | Frequency and Intensity of exposure [ |
| Ethnicity (Immune characteristics) [ | Presence of other | ||
| Nutritional status [ | Presence of other pathogens [ | ||
| Acquired immunity [ | |||
| Innate immunity [ | |||
| Immune profile [ | |||
| Level of exposure | |||
| Presence of concurrent infections [ |